Cell cycle-specific function of Ikaros in human leukemia

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 69-76

  Li, Zhanjun ^a,b   Song, Chunhua ^a   Ouyang, Hongsheng ^b   Lai, Liangxue ^b   Payne, Kimberly J ^c   Dovat, Sinisa ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

Casein kinase 2; Cell cycle; Ikaros; Isoforms; Leukemia; Phosphorylation

Indexed keywords

CASEIN KINASE II; GENOMIC DNA; IKAROS TRANSCRIPTION FACTOR; ISOPROTEIN; PHOSPHOPEPTIDE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; B CELL LEUKEMIA; BINDING AFFINITY; CELL CYCLE PROGRESSION; CENTROMERE; CONFOCAL MICROSCOPY; GEL MOBILITY SHIFT ASSAY; GENE MAPPING; HETEROCHROMATIN; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; T CELL LEUKEMIA;

CASEIN KINASE II; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IKAROS TRANSCRIPTION FACTOR; LEUKEMIA, B-CELL; LEUKEMIA, T-CELL; NEOPLASM PROTEINS; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ISOFORMS; S PHASE;

EID: 84861208113     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23406     Document Type: Article

References (48)

1. Nichogiannopoulou A, Trevisan M, Neben S, et al. Defects in hemopoietic stem cell activity in Ikaros mutant mice. J Exp Med 1999; 190: 1201-1214.
2. Wang JH, Nichogiannopoulou A, Wu L, et al. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 1996; 5: 537-549.
3. Lopez RA, Schoetz S, DeAngelis K, et al. Multiple hematopoietic defects and delayed globin switching in Ikaros null mice. Proc Natl Acad Sci U S A 2002; 99: 602-607.
4. Papathanasiou P, Perkins AC, Cobb BS, et al. Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor. Immunity 2003; 19: 131-144.
5. Dumortier A, Kirstetter P, Kastner P, et al. Ikaros regulates neutrophil differentiation. Blood 2003; 101: 2219-2226.
6. Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 1995; 83: 289-299.
7. Okano H, Saito Y, Miyazawa T, et al. Homozygous deletions and point mutations of the Ikaros gene in gamma- ray-induced mouse thymic lymphomas. Oncogene 1999; 18: 6677-6683.
8. Rebollo A, Schmitt C. Ikaros, Aiolos and Helios: Transcription regulators and lymphoid malignancies. Immunol Cell Biol 2003; 81: 171-175.
9. Ronni T, Payne KJ, Ho S, et al. Human Ikaros function in activated T cells is regulated by coordinated expression of its largest isoforms. J Biol Chem 2007; 282: 2538-2547.
10. Payne KJ, Nicolas JH, Zhu JY, et al. Cutting edge: Predominant expression of a novel Ikaros isoform in normal human hemopoiesis. J Immunol 2001; 167: 1867-1870.
11. Payne KJ, Huang G, Sahakian E, et al. Ikaros isoform x is selectively expressed in myeloid differentiation. J Immunol 2003; 170: 3091-3098.
12. Kim JH, Ebersole T, Kouprina N, et al. Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing. Genome Res 2009; 19: 533-544.
13. Dovat S, Ronni T, Russell D, et al. A common mechanism for mitotic inactivation of C2H2 zinc finger DNA-binding domains. Genes Dev 2002; 16: 2985-2990.
14. Francis OL, Payne JL, Su RJ, et al. Regulator of myeloid differentiation and function: The secret life of Ikaros. World J Biol Chem 2011; 2: 119-125.
15. Li Z, Perez-Casellas LA, Savic A, et al. Ikaros isoforms: The saga continues. World J Biol Chem 2011; 2: 140-145.
16. Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. Embo J 1996; 15: 5358-5369.
17. Brown KE, Guest SS, Smale ST, et al. Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin. Cell 1997; 91: 845-854.
18. Liberg D, Smale ST, Merkenschlager M. Upstream of Ikaros. Trends Immunol 2003; 24: 567-570.
19. Gurel Z, Ronni T, Ho S, et al. Recruitment of ikaros to pericentromeric heterochromatin is regulated by phosphorylation. J Biol Chem 2008; 283: 8291-8300.
20. Popescu M, Gurel Z, Ronni T, et al. Ikaros stability and pericentromeric localization are regulated by protein phosphatase 1. J Biol Chem 2009; 284: 13869-13880.
21. Song C, Li Z, Erbe AK, et al. Regulation of Ikaros function by casein kinase 2 and protein phosphatase 1. World J Biol Chem 2011; 2: 126-131.
22. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
23. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
24. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 2007; 21: 1258-1266.
25. Marcais A, Jeannet R, Hernandez L, et al. Genetic inactivation of Ikaros is a rare event in human T-ALL. Leuk Res 2010; 34: 426-429.
26. Dovat S, Payne KJ. Tumor suppression in T cell leukemia-the role of Ikaros. Leuk Res 2010; 34: 416-417.
27. Hunger SP, Raetz EA, Loh ML, et al. Improving outcomes for high-risk ALL: Translating new discoveries into clinical care. Pediatr Blood Cancer 2011; 56: 984-993.
28. Mullighan CG. Genetic variation and the risk of acute lymphoblastic leukemia. Leuk Res 2010; 34: 1269-1270.
29. Mullighan CG. New strategies in acute lymphoblastic leukemia: Translating advances in genomics into clinical practice. Clin Cancer Res 2011; 17: 396-400.
30. Sun L, Heerema N, Crotty L, et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1999; 96: 680-685.
31. Nakase K, Ishimaru F, Avitahl N, et al. Dominant negative isoform of the Ikaros gene in patients with adult B- cell acute lymphoblastic leukemia. Cancer Res 2000; 60: 4062-4065.
32. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
33. Kastner P, Chan S. Role of Ikaros in T-cell acute lymphoblastic leukemia. World J Biol Chem 2011; 2: 108-114.
34. Dovat S, Song C, Payne KJ, et al. Ikaros, CK2 kinase, and the road to leukemia. Mol Cell Biochem 2011; [Epub ahead of print].
35. Hahm K, Ernst P, Lo K, et al. The lymphoid transcription factor LyF-1 is encoded by specific, alternatively spliced mRNAs derived from the Ikaros gene. Mol Cell Biol 1994; 14: 7111-7123.
36. Goldman FD, Gurel Z, Al-Zubeidi D, et al. Congenital pancytopenia and absence of B lymphocytes in a neonate with a mutation in the ikaros gene. Pediatr Blood Cancer 2011; [Epub ahead of print].
37. Wargnier A, Lafaurie C, Legros-Maida S, et al. Down-regulation of human granzyme B expression by glucocorticoids. Dexamethasone inhibits binding to the Ikaros and AP-1 regulatory elements of the granzyme B promoter. J Biol Chem 1998; 273: 35326-35331.
38. Ghanshani S, Wulff H, Miller MJ, et al. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J Biol Chem 2000; 275: 37137-37149.
39. Ahmad KA, Wang G, Slaton J, et al. Targeting CK2 for cancer therapy. Anticancer Drugs 2005; 16: 1037-1043.
40. Kim JS, Eom JI, Cheong JW, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007; 13: 1019-1028.
41. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 2002; 21: 5280-5288.
42. Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. Embo J 1996; 15: 5160-5166.
43. Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: Relation to theileriosis in cattle. Science 1995; 267: 894-897.
44. Martins LR, Lucio P, Silva MC, et al. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood 2010; 116: 2724-2731.
45. Gomez-del Arco P, Maki K, Georgopoulos K. Phosphorylation controls Ikaros's ability to negatively regulate the G(1)-S transition. Mol Cell Biol 2004; 24: 2797-2807.
46. Sun L, Goodman PA, Wood CM, et al. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 3753-3766.
47. Cobb BS, Morales-Alcelay S, Kleiger G, et al. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes and Development 2000; 14: 2146-2160.
48. Kathrein KL, Lorenz R, Innes AM, et al. Ikaros induces quiescence and T-cell differentiation in a leukemia cell line. Mol Cell Biol 2005; 25: 1645-1654.